The GO2 Foundation for Lung Cancer is an organisation founded by patients and survivors of lung cancer that aims to save, extend, and improve the lives of those with lung cancer. They have nearly 800 centres throughout the US and provide screening, education, and support services. They conduct annual surveys to provide both qualitative and quantitative data about the journey of patients with lung cancer. In 2020, additional questions were added to assess the impact of COVID-19 on this journey. Ms Rashmi Acharya (GO2 Foundation for Lung Cancer, USA) presented the survey findings.
Among the 27 centres that responded to the survey, 60% noted a decrease in the number of new lung cancer diagnoses during the pandemic as compared with 2019. Centres consistently expressed concern that patients with lung cancer would experience delayed diagnosis and/or treatment due to the pandemic.
In 2020, the support helpline offered by the foundation reported a 35% decrease in call volume. The average change in helpline usage between quarters 1 and 2 in 2018 and 2019 was 3%; in 2020, there was a 13% decrease in helpline usage during this same period.
There was also a considerable decrease in the number of requests from healthcare providers for printed educational materials; requests in 2020 were down by 38% as compared with the previous year.
The researchers concluded that these findings highlight the impact that COVID-19 has had, and is continuing to have, on patients with lung cancer. They further stated that these data are important to help prepare for the post-pandemic period.
- Acharyha R. Impact of COVID-19 on lung cancer care and utilisation of patient support resources. MA 05.02, WCLC 2021, 8–14 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Experiences of lung cancer patients during COVID-19: survey finds room for improvement Next Article
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment »
« Experiences of lung cancer patients during COVID-19: survey finds room for improvement Next Article
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment »
Table of Contents: WCLC 2021
Featured articles
Atezolizumab promising for treating NSCLC brain metastases
Novel Therapy Approaches
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
COVID-19
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Evidence-Based Advocacy
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Response Predictors
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
Related Articles
August 12, 2021
Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com